Manheim L M
Institute for Health Services Research and Policy Studies, Northwestern University, Evanston, IL 60208, USA.
Control Clin Trials. 1998 Apr;19(2):149-58. doi: 10.1016/s0197-2456(97)00146-3.
The costs and benefits of treatment interventions are difficult both to conceptualize and to measure. This paper discusses methodologic issues that arise in measuring costs, distinguishing between social costs and transfer payments, measuring the value of life and limb, and assessing the meaning of cost differences. Long-run vs. short-run costs and average vs. marginal costs are considered. Sensitivity analysis to assess the robustness of results to alternative assumptions is stressed. Cost-benefit and cost-effectiveness analyses are seen as important in assessing the policy implications of clinical trials; a proper cost-benefit analysis allows the reader to understand how results relate to the assumptions made in the analyses.
治疗干预措施的成本和收益在概念化和衡量方面都很困难。本文讨论了在衡量成本、区分社会成本和转移支付、衡量生命和肢体的价值以及评估成本差异的意义时出现的方法学问题。文中考虑了长期成本与短期成本以及平均成本与边际成本。强调了进行敏感性分析以评估结果对替代假设的稳健性。成本效益分析和成本效果分析在评估临床试验的政策影响方面被视为很重要;恰当的成本效益分析能让读者理解结果与分析中所做假设之间的关系。